SS
TARA icon

SBI Securities’s Protara Therapeutics TARA Stock Holding History

SBI Securities’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$393 Hold
103
– – ﹤0.01% 3123
2026
Q1 		$537 Hold
103
– – ﹤0.01% 2872
2025
Q4 		$549 Sell
103
-2
-2% -$11 ﹤0.01% 2840
2025
Q3 		$457 Buy
105
+2
+2% +$6 ﹤0.01% 3008
2025
Q2 		$312 Sell
103
-40
-28% -$138 ﹤0.01% 3162
2025
Q1 		$609 Buy
143
+40
+39% +$179 ﹤0.01% 2787
2024
Q4 		$544 Buy
+103
New +$333 ﹤0.01% 2860

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

SBI Securities's TARA Position: Q2 2026 in Review

SBI Securities held its Protara Therapeutics (TARA) position steady in Q2 2026 at 103 shares worth $393. The position accounts for ﹤0.01% of the portfolio, ranked #3123.

SBI Securities first reported a position in TARA in Q4 2024 and has held it in 7 quarters since. The position peaked at $609 in Q1 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • SBI Securities held 103 shares of Protara Therapeutics worth $393 as of Q2 2026.
  • SBI Securities left its Protara Therapeutics share count unchanged in Q2 2026.
  • Protara Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3123 holding.
  • SBI Securities first reported a position in Protara Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • SBI Securities's Protara Therapeutics position peaked at $609 in Q1 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.